Colla Laboratory
Simona Colla, Ph.D.
Principal Investigator
- Departments, Labs and Institutes
- Labs
- Colla Laboratory
Areas of Research
- Leukemia
- Myelodysplastic Syndrome
- Cancer Biology
- Molecular Biology
- Mouse Model Development
- Single-Cell Genomics
Welcome to the Colla Lab at MD Anderson Cancer Center. We are a basic and translational lab in the Leukemia department. Our researchers use multidisciplinary approaches and model systems to gain a deep understanding of the cellular and molecular mechanisms that drive hematologic malignancies (blood cancers).
Our goal is to improve the clinical outcome of patients with Myelodysplastic Syndromes (MDS) and Multiple Myeloma (MM) by making scientific advances that allow us to better understand the molecular mechanisms that drive these hematological malignancies.
Specific Aims
- Identify biological mechanisms of therapeutic resistance and develop successful strategies to overcome this resistance
- Leverage insights from basic studies to identify targetable networks
- In vivo analysis to test drug efficacy to develop novel therapies
To develop novel treatment strategies, our research employs an integrative toolbox that includes genomic, molecular, proteomic and cellular analyses, as well as PDX and GEM mouse models.
Recent Publications
-
Cell Reports Medicine
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation Opens a new window
Juan Jose Rodriguez-Sevilla and Simona Colla
-
Preprint
Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma Opens a new window
Natthakan Thongon and Simona Colla
-
Preprint
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia Opens a new window
Guillermo Montalban-Bravo and Simona Colla
Funding
Funding support for the Colla Laboratory includes the Leukemia and Lymphoma Society, MD Anderson Cancer Center Moon Shots Program®, National Institutes of Health/National Cancer Institute and Evans MDS Foundation.